La Clinica terapeutica · 2026
Plasma Asymmetric Dimethylarginine as a Biomarker of Disease Severity and Therapeutic Response in Neonatal Persistent Pulmonary Hypertension: An Observational Prospective Case-Control Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdou Rania M, El Wakeel Maged A, El-Kassas Ghada M, Ali Walaa H, Ahmed Hend M, Agha Mohamed, Abdel Fatah Mohamed Abdel Atti, Abdelghany Ramy Saleh, Madbouly Kareem Salah Eldin Fekry, Mohamad Haidy Badei, Hassan Iman Shawky, Ahmed Mohamed Abdelsalam Mohamed, Okda Heba T, Ismail Hatem Attia Mostafa
Аннотация
BACKGROUND: Persistent pulmonary hypertension of the newborn (PPHN) is a life-threatening condition characterized by elevated pulmonary vascular resistance and impaired oxygenation. Endothelial dysfunction plays a central role in its pathophysiology. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, has been implicated in pulmonary vascular disease; however, its clinical utility as a biomarker of disease severity and therapeutic response in neonatal PPHN remains insufficiently defined.
METHODS: This prospective observational case-control study included neonates diagnosed with PPHN and age- and sex-matched healthy controls. Plasma ADMA levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical severity was assessed using oxygenation index (OI) and echocardiographic parameters. Associations between ADMA levels, disease severity, and therapeutic response were analyzed using correlation analysis, multivariable regression models, and receiver operating characteristic (ROC) curve analysis.
RESULTS: Neonates with PPHN demonstrated significantly elevated plasma ADMA levels compared with controls (p < 0.001). ADMA levels showed a positive correlation with oxygenation index and echocardiographic markers of pulmonary hypertension severity. Higher baseline ADMA concentrations were independently associated with increased disease severity after adjustment for relevant confounders. ROC curve analysis demonstrated good discriminatory performance of ADMA in identifying severe PPHN. Additionally, declining ADMA levels were associated with clinical improvement following standard therapeutic interventions.
CONCLUSION: Plasma ADMA levels are significantly elevated in neonates with PPHN and correlate with disease severity and therapeutic response. ADMA may serve as a promising biomarker for risk stratification and monitoring in neonatal PPHN. Larger multicenter studies are warranted to validate these findings and explore its prognostic utility.
METHODS: This prospective observational case-control study included neonates diagnosed with PPHN and age- and sex-matched healthy controls. Plasma ADMA levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical severity was assessed using oxygenation index (OI) and echocardiographic parameters. Associations between ADMA levels, disease severity, and therapeutic response were analyzed using correlation analysis, multivariable regression models, and receiver operating characteristic (ROC) curve analysis.
RESULTS: Neonates with PPHN demonstrated significantly elevated plasma ADMA levels compared with controls (p < 0.001). ADMA levels showed a positive correlation with oxygenation index and echocardiographic markers of pulmonary hypertension severity. Higher baseline ADMA concentrations were independently associated with increased disease severity after adjustment for relevant confounders. ROC curve analysis demonstrated good discriminatory performance of ADMA in identifying severe PPHN. Additionally, declining ADMA levels were associated with clinical improvement following standard therapeutic interventions.
CONCLUSION: Plasma ADMA levels are significantly elevated in neonates with PPHN and correlate with disease severity and therapeutic response. ADMA may serve as a promising biomarker for risk stratification and monitoring in neonatal PPHN. Larger multicenter studies are warranted to validate these findings and explore its prognostic utility.